Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

There's a catch, however: Given as either a pill or injection and currently branded as Sunlenca, lenacapavir as treatment for ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

In a study of 12 participants, researchers at Beth Israel Deaconess Medical Center (BIDMC) have demonstrated that a cocktail ...

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

In the 80′s, contracting HIV was considered a death sentence. In the 90′s, HIV was the number one cause of death among ...

HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...

Young people living with HIV play a critical role in the fight against AIDS in communities. They offer support and share ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has raised alarm over the increasing incidence of HIV among young ...